682 related articles for article (PubMed ID: 33278816)
1. Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
Drevin G; Picard N; Jousset N; Briet M; Abbara C
Forensic Sci Int Genet; 2021 Mar; 51():102433. PubMed ID: 33278816
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.
Karlsson L; Zackrisson AL; Josefsson M; Carlsson B; Green H; Kugelberg FC
Pharmacogenomics J; 2015 Apr; 15(2):165-71. PubMed ID: 25245581
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
[TBL] [Abstract][Full Text] [Related]
4. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.
Shen C; Yang H; Shao W; Zheng L; Zhang W; Xie H; Jiang X; Wang L
Pharm Res; 2024 Apr; 41(4):731-749. PubMed ID: 38443631
[TBL] [Abstract][Full Text] [Related]
6. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
Kringen MK; Bråten LS; Haslemo T; Molden E
J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
[TBL] [Abstract][Full Text] [Related]
7. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
[TBL] [Abstract][Full Text] [Related]
8. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.
Scherf-Clavel M; Frantz A; Eckert A; Weber H; Unterecker S; Deckert J; Reif A; Hahn M
Int J Clin Pharm; 2023 Oct; 45(5):1107-1117. PubMed ID: 37166747
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
[TBL] [Abstract][Full Text] [Related]
11. The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.
Scherf-Clavel M; Weber H; Unterecker S; Frantz A; Eckert A; Reif A; Deckert J; Hahn M
Pharmacopsychiatry; 2024 Mar; 57(2):69-77. PubMed ID: 38354747
[TBL] [Abstract][Full Text] [Related]
12. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths.
Aly SM; Hennart B; Gaulier JM; Allorge D
Toxics; 2024 Mar; 12(4):. PubMed ID: 38668482
[TBL] [Abstract][Full Text] [Related]
15. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
Nahid NA; Johnson JA
Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):769-785. PubMed ID: 36597259
[TBL] [Abstract][Full Text] [Related]
17. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
19. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
Ther Drug Monit; 2016 Feb; 38(1):127-34. PubMed ID: 26418700
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.
Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]